622 completed, 61 terminated, 46 unknown, 43 recruiting. 826 Phase 3, 70 Phase 2.
By phase and status
Phase Trials Status Phase 3 826 Completed 622 , Terminated 61 , Unknown 46 , Recruiting 43 , Withdrawn 26 , Active not recruiting 15 , Not yet recruiting 11 , Enrolling by invitation 1 , Suspended 1 Phase 2 70 Completed 47 , Unknown 10 , Withdrawn 6 , Terminated 4 , Active not recruiting 2 , Not yet recruiting 1
Follow Bronchial Diseases: new trials by email Literature Review of Bronchial Diseases trials Research Report on Bronchial Diseases
Trials (filtered) newest first · largest first
All 826 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With Asthma CHF5993 100/6/12.5 μg pMDI HFA-152a, Seretide Evohaler - Asthma Phase 3 Not yet recruiting 700 2026-11-16 2026-10-05 A Study to Evaluate the Efficacy and Safety of CHF10196 Tablets (Florensocatib) Compared With Placebo in Male and Female Participants 12 to 85 Years of Age With Bronchiectasis CHF10196 tablets (florensocatib), Placebo - Bronchiectasis Phase 3 Not yet recruiting 904 2026-11-01 2026-06-24 Study of Formoterol 6 mcg/Fluticasone 125 mcg by Eurofarma Laboratórios S.A. Versus Alenia® 6 mcg/200 mcg in Patients With Asthma (FORASMA) N0783, Alenia® (Formoterol 6 mcg / Budesonide 200 mcg) - Moderate Asthma Phase 3 Withdrawn 2026-10-01 2026-10-23 A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma tilrekimig, Placebo - Asthma Phase 3 Recruiting 1100 2026-09-30 2026-10-09 A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease Belumosudil, Best available therapy (BAT) - Chronic Graft Versus Host Disease Phase 3 Not yet recruiting 356 2026-09-07 2026-09-15 A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a) HFA-152a, HFA-134a - Asthma Phase 3 Recruiting 110 2026-09-01 2026-09-30 A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-2) GSK5784283, Placebo, Standard of care - Asthma Phase 3 Recruiting 370 2026-08-27 2026-09-30 A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-1) GSK5784283, Placebo, Standard of care - Asthma Phase 3 Recruiting 514 2026-08-27 2026-09-25 A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma tilrekimig, Placebo - Asthma Phase 3 Recruiting 1100 2026-08-20 2026-10-06 A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma. QVM149, Salmeterol Xinafoate / Fluticasone Propionate, Placebo to QVM149 - Asthma Phase 3 Recruiting 188 2026-08-04 2026-10-15 Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment Benralizumab - Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA) Phase 3 Recruiting 230 2026-07-24 2026-10-27 Efficacy and Safety of CHF 5993 100/6/12.5 μg HFA-152a pMDI in Patients With Asthma Uncontrolled on Medium Doses of Inhaled Corticosteroids in Combination With Long-acting ß2-agonists Experimental: Participant Group CHF 5993 pMDI HFA-152a, Active Comparator: CHF 1535 100/6 μg pMDI HFA-134a - Asthma Phase 3 Recruiting 554 2026-06-26 2026-07-08 A Study of Depemokimab in Participants of 6 to 11 Years of Age Depemokimab - Asthma Phase 3 Recruiting 34 2026-06-25 2026-08-26 Beclometasone Dipropionate and Formoterol Inhalation Aerosol for Asthma Beclometasone Dipropionate and Formoterol Inhalation Aerosol, FOSTER® - Asthma (Diagnosis) Phase 3 Recruiting 416 2026-06-08 2026-08-17 A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma Depemokimab, Placebo - Asthma Phase 3 Recruiting 456 2026-03-13 2026-08-17 A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma Dupilumab Prefilled Syringe, Placebo Injection - Asthma Control Phase 3 Recruiting 150 2026-01-29 2026-10-02 Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab Tezepelumab - Severe Asthma Phase 3 Recruiting 400 2026-01-28 2026-09-03 A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2) GB-0895, Placebo - Severe Asthma Phase 3 Recruiting 786 2026-01-20 2026-10-20 Compare the Efficacy and Safety of QL2302 Versus Tezspire® in Severe Asthma tezepelumab (Arm1&Arm2) - Asthma Phase 3 Not yet recruiting 636 2025-12-25 2025-12-24 Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations Firmonertinib, EGFR-TKI inhibitor based on investigator's choice - Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer Phase 3 Recruiting 480 2025-12-17 2026-10-14
Showing 20 of 826. Sign in to see all of them.
Narrower conditions Asthma (605) · Bronchiolitis Obliterans Syndrome (86) · Pulmonary Disease, Chronic Obstructive (39) · Lung Diseases (38) · Bronchitis, Chronic (31) · Bronchitis (29) · Respiratory Tract Diseases (29) · Bronchiolitis (27) · Bronchiectasis (26) · Lung Diseases, Obstructive (23) · Emphysema (16) · Hypersensitivity (15) · Bronchiolitis Obliterans (12) · Pulmonary Eosinophilia (12)
Broader conditions Respiratory Tract Diseases (797) · Lung Diseases (758) · Lung Diseases, Obstructive (758) · Immune System Diseases (699) · Hypersensitivity, Immediate (616) · Respiratory Hypersensitivity (611) · Hypersensitivity (603) · Pathological Conditions, Signs and Symptoms (147) · Bronchitis (146) · Infections (108) · Bronchiolitis (97) · Respiratory Tract Infections (87) · Organizing Pneumonia (86) · Bronchiolitis Obliterans (83)
Interventions Budesonide (75) · Fluticasone (53) · Albuterol (51) · Formoterol Fumarate (49) · Budesonide, Formoterol Fumarate Drug Combination (48) · montelukast (41) · Salmeterol Xinafoate (32) · Beclomethasone (31) · Fluticasone-Salmeterol Drug Combination (26) · ciclesonide (25) · benralizumab (22) · Omalizumab (20) · fluticasone furoate (18) · Azithromycin (17) · tezepelumab (16)
Sponsors AstraZeneca (129) · GlaxoSmithKline (65) · Organon and Co (38) · Novartis Pharmaceuticals (28) · Chiesi Farmaceutici S.p.A. (25) · Teva Branded Pharmaceutical Products R&D, Inc. (23) · Boehringer Ingelheim (18) · Sanofi (18) · Milton S. Hershey Medical Center (17) · Pfizer (15) · Sumitomo Pharma America, Inc. (15) · Assistance Publique - Hôpitaux de Paris (9) · Hoffmann-La Roche (8) · Amphastar Pharmaceuticals, Inc. (7) · Novartis (7)
Countries United States (346) · Germany (163) · Canada (149) · Poland (142) · United Kingdom (124) · Spain (121) · France (114) · Argentina (99) · Italy (98) · Russia (97) · Hungary (96) · Japan (87) · Australia (85) · South Korea (85) · Mexico (82)
Top investigators Catherine Bonuccelli (11) · Esther Garcia, MD (7) · Elliot Israel, MD (6)
Results publications PMID 36472162 , PMID 27881132 , PMID 31319851 , PMID 32816215 , PMID 39393433 , PMID 29174062 , PMID 30954640 , PMID 32180164 , PMID 22329608 , PMID 24966061 , PMID 26369589 , PMID 26498386 , PMID 26612545 , PMID 26704701 , PMID 29536781 , PMID 30802500 , PMID 31047111 , PMID 31251094 , PMID 31447130 , PMID 31760132 , PMID 33217063 , PMID 33223095 , PMID 34098955 , PMID 35287231 , PMID 35636689 , PMID 36356712 , PMID 36702146 , PMID 19995138 , PMID 20075384 , PMID 20835586 , PMID 22938706 , PMID 24314123 , PMID 24838406 , PMID 25154045 , PMID 25682232 , PMID 25724847 , PMID 26149717 , PMID 26233481 , PMID 27087007 , PMID 27216137 , PMID 27616196 , PMID 27912982 , PMID 28069068 , PMID 28396102 , PMID 28495619 , PMID 28558833 , PMID 28624608 , PMID 29409951 , PMID 29949045 , PMID 30077185
NIH funding 2015 (15) , 2023 (15) , 2016 (14) , 2009 (8) , 2017 (8) , 2018 (8) , 2014 (7) , U10HL098115 (7) , 2008 (5) , U10HL074073 (5) , U10HL074204 (5) , U10HL074208 (5) , U10HL074212 (5) , U10HL074218 (5) , U10HL074225 (5)